When Using Foreign Clinical Data, Be Prepared To Prove U.S. Applicability

When using data from clinical trials conducted outside the U.S. for an NDA, drug makers must be able to demonstrate that the data are applicable to the U.S. population and U.S. medical practice, Murray Lumpkin, FDA's deputy commissioner for international programs, said